

PUBBLICAZIONI CTMO- ANNO 2022

1. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.

Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C. *Int J Mol Sci.* 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. PMID: 36362130 Free PMC article

2. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.

Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantonio G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. *HematolOncol.* 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. PMID: 35608183

3. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.

Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, Koc Y, Gülbas Z, Vitek A, Sica S, Diez-Martin JL, Castagna L, Bruno B, Rovira M, Moiseev I, Martino M, Grillo G, Araujo MC, Bulabois CE, Nguyen S, Socié G, Arat M, Pavlu J, Tischer J, Martin H, Corral LL, Choi G, Forcade E, McDonald A, Pane F, Bazarbachi A, Ciceri F, Nagler A, Mohty M. *Bone MarrowTransplant.* 2022 Apr;57(4):562-571. doi: 10.1038/s41409-022-01577-x. Epub 2022 Jan 25. PMID: 35079140

4. Identifying and managing CAR T-cell- mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team.

Martino M, Macheda S, Aguglia U, Arcudi L, Pucci G, Martino B, Altomonte M, Rossetti AM, Cusumano G, Russo L, Imbalzano L, Stelitano C, Alati C, Germano' J, Labate D, Amalfi V, Florenzano MT, Morabito A, Borzumati V, Dattola V, Gattuso C, Moschella A, Quattrone D, Curmaci F, Franzutti C, Scappatura G, Rao CM, Loddo V, Pontari A, Pellicano' M, Surace R, Sanguedolce C, Naso V, Ferreri A, Irrera G, Console G, Moscato T, Loteta B, Canale FA, Trimarchi A, Monteleone R, Al Sayyad S, Cirrone F, Bruno B. *Expert OpinBiolTher.* 2022 Mar;22(3):407-421. doi: 10.1080/14712598.2021.1974394. Epub 2021 Sep 15. PMID: 34463175

5. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide.

Mariotti J, Raiola AM, Evangelista A, Harbi S, Patriarca F, Carella MA, Martino M, Risitano A, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Chabannon C, Furst S, Santoro A, Bacigalupo A, Bruno B,

Blaise D, Mavilio D, Bramanti S, Devillier R, Angelucci E, Castagna L. Bone MarrowTransplant. 2022 Sep 3. doi: 10.1038/s41409-022-01565-1. Online ahead of print. PMID: 36057732

6. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.

Bonifazi F, Pavoni C, Peccatori J, Giglio F, Arpinati M, Busca A, Bernasconi P, Grassi A, Iori AP, Patriarca F, Brunello L, Di Grazia C, Carella AM, Cilloni D, Picardi A, Proia A, Santarone S, Sorasio R, Carluccio P, Chiusolo P, Cupri A, Luppi M, Nozzoli C, Baronciani D, Casini M, Grillo G, Musso M, Onida F, Palazzo G, Parma M, Tringali S, Vacca A, Vallisa D, Sacchi N, Oldani E, Masciulli A, Gheorghiu A, Girmenia C, Martino M, Bruno B, Rambaldi A, Ciceri F; GITMO. Bone MarrowTransplant. 2022 Jun;57(6):949-958. doi: 10.1038/s41409-022-01626-5. Epub 2022 Apr 12. PMID: 35413985.

7. The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.

Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, Gülbas Z, Diez-Martin JL, Bruno B, Castagna L, Martino M, Rovira M, Mohty M, Nagler A. Bone MarrowTransplant. 2022 Mar;57(3):384-390. doi: 10.1038/s41409-021-01493-6. Epub 2022 Jan 13. PMID: 35022535

8. Comparison between peripheral blood progenitor cell collection on the 4th or 5th day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines.

Passeri C, Iuliani O, Di Ianni M, Sorrentino C, Giancola R, Abbruzzese L, Dallavalle FM, Gattillo S, Mariano MT, Martino M, Ostuni A, Savignano C, Santoleri L, Tison T, Vacca M, Accorsi P. Blood Transfus. 2022 Aug 9. doi: 10.2450/2022.0026-22. Online ahead of print. PMID: 35969140

9. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study.

Martino M, Pitino A, Gori M, Viens P, Siena S, Tripepi G, Canale FA, Ballestrero A, Zamagni C, Musso M, Zambelli A, Dreger P, Badoglio M, Secondino S, Console G, Chabannon C, Pedrazzoli P; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP). Bone MarrowTransplant. 2022 Feb;57(2):276-278. doi: 10.1038/s41409-021-01503-7. Epub 2021 Oct 23. PMID: 34689176

10. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.

Delia M, Carluccio P, Gagliardi VP, Mestice A, Chiusolo P, Arpinati M, Milone GA, Martino M, Mazza P, Ingrosso C, Vacca A, Saporiti G, Zallio F, Attolico I, Pastore D, Specchia G, Albano F, Musto P. Bone MarrowTransplant. 2022 Jun;57(6):1042-1044. doi: 10.1038/s41409-022-01676-9. Epub 2022 Apr 19. PMID: 35440806

11. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥ 60 Years from 2000 to 2017: Improvements and Criticisms.

Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, De Gobbi M, Natale A, Terruzzi E, Olivieri A, Chiusolo P, Carella AM, Casini M, Nozzoli C, Mazza P, Bassi S, Onida F, Vacca A, Falcioni S, Luppi M, Iori AP, Pavone V, Skert C, Carluccio P, Borghero C, Proia A, Selleri C, Sacchi N, Mammoliti S, Oldani E, Ciceri F, Russo D, Bonifazi F. *Transplant Cell Ther.* 2022 Feb;28(2):96.e1-96.e11. doi: 10.1016/j.jtct.2021.11.006. Epub 2021 Nov 21. PMID: 34818581

12. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.

Loteta B, Paviglianiti A, Naso V, Ferreri A, Moscato T, Console G, Canale FA, Irrera G, Pugliese M, Di Costanzo A, Provenzano PF, Loddo V, Porto G, Cusumano G, Russo L, Meliambro N, Romeo V, Porcino D, Gallo S, Gangemi T, Rossetti AM, Martino M. *Support Care Cancer.* 2022 Jan;30(1):585-591. doi: 10.1007/s00520-021-06472-7. Epub 2021 Aug 4. PMID: 34347181

13. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT.

Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, Stölzel F, Bug G, Bruno B, Vrhovac R, Charbonnier A, Olivieri A, Bay JO, Arroyo H, Yakoub-Agha I, Avenoso D, Neubauer A, Nguyen S, Forcade E, Brissot E, Savani B, Nagler A, Mohty M. *Bone Marrow Transplant.* 2022 Sep;57(9):1421-1427. doi: 10.1038/s41409-022-01674-x. Epub 2022 Jun 25. PMID: 35752739

14. Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.

Candoni A, Lazzarotto D, Rambaldi A, Dubbini MV, Bresciani P, Busca A, Arcese W, Iori AP, Sorasio R, Irrera G, Fanin R, Ciceri F, Bonifazi F; GITMO. *Bone Marrow Transplant.* 2022 May;57(5):834-836. doi: 10.1038/s41409-022-01618-5. Epub 2022 Feb 24. PMID: 35210562

15. Comprehensive UHPLC- and CE-based methods for engineered Cas9 characterization.

Camperi J, Console G, Zheng L, Stephens N, Montti M, Roper B, Zheng M, Moshref M, Dagdas Y, Holder P, Stella C. *Talanta.* 2023 Jan 15;252:123780. doi: 10.1016/j.talanta.2022.123780. Epub 2022 Aug 9. PMID: 35988299